89 related articles for article (PubMed ID: 20811663)
1. p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma.
Kudo I; Esumi M; Kida A; Ikeda M
Oncol Rep; 2010 Oct; 24(4):851-6. PubMed ID: 20811663
[TBL] [Abstract][Full Text] [Related]
2. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
3. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
4. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
Mandic R; Schamberger CJ; Müller JF; Geyer M; Zhu L; Carey TE; Grénman R; Dünne AA; Werner JA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6845-52. PubMed ID: 16203773
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines.
Yu ZW; Zhong LP; Ji T; Zhang P; Chen WT; Zhang CP
Oral Oncol; 2010 Apr; 46(4):317-22. PubMed ID: 20219416
[TBL] [Abstract][Full Text] [Related]
6. Changes of mutant-type p53 expression in squamous cell carcinoma of the head and neck during radiation therapy and its clinical significance: comparison of an immunohistochemical method and PCR-SSCP assay.
Ogawa Y; Nishioka A; Hamada N; Terashima M; Inomata T; Yoshida S; Seguchi H; Kishimoto S
Oncol Rep; 1998; 5(5):1053-9. PubMed ID: 9683807
[TBL] [Abstract][Full Text] [Related]
7. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
[TBL] [Abstract][Full Text] [Related]
8. Factors involved in the cisplatin resistance of KCP‑4 human epidermoid carcinoma cells.
Oiso S; Takayama Y; Nakazaki R; Matsunaga N; Motooka C; Yamamura A; Ikeda R; Nakamura K; Takeda Y; Kariyazono H
Oncol Rep; 2014 Feb; 31(2):719-26. PubMed ID: 24317338
[TBL] [Abstract][Full Text] [Related]
9. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-induced genes as potential markers for thyroid cancer.
Lapouge G; Millon R; Muller D; Abecassis J; Eber M; Bergerat JP; Klein-Soyer C
Cell Mol Life Sci; 2005 Jan; 62(1):53-64. PubMed ID: 15619007
[TBL] [Abstract][Full Text] [Related]
11. Appearance of drug-resistant tumor cells in a maxillary cancer patient undergoing chemotherapy and chemoradiotherapy.
Kudoh S; Komiyama S; Miyazaki H; Matsui K
Am J Otolaryngol; 1990; 11(3):165-9. PubMed ID: 1696435
[TBL] [Abstract][Full Text] [Related]
12. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma.
Hoffmann TK; Sonkoly E; Hauser U; van Lierop A; Whiteside TL; Klussmann JP; Hafner D; Schuler P; Friebe-Hoffmann U; Scheckenbach K; Erjala K; Grénman R; Schipper J; Bier H; Balz V
Oral Oncol; 2008 Dec; 44(12):1100-9. PubMed ID: 18487078
[TBL] [Abstract][Full Text] [Related]
13. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
14. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
15. [Establishment and drug-resistance gene expression of cisplatin-resistant cell line Tca8113/CDDP].
Zhou XJ; Li Q; Chen WT
Shanghai Kou Qiang Yi Xue; 2003 Dec; 12(6):432-5. PubMed ID: 14966583
[TBL] [Abstract][Full Text] [Related]
16. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
[TBL] [Abstract][Full Text] [Related]
17. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
[TBL] [Abstract][Full Text] [Related]
18. Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Rigalli JP; Reuter T; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Theile D
Cancer Chemother Pharmacol; 2013 May; 71(5):1335-43. PubMed ID: 23479137
[TBL] [Abstract][Full Text] [Related]
19. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Theile D; Ketabi-Kiyanvash N; Herold-Mende C; Dyckhoff G; Efferth T; Bertholet V; Haefeli WE; Weiss J
Head Neck; 2011 Jul; 33(7):959-68. PubMed ID: 20737486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
